Abstract：
BACKGROUND: To study the various factors affecting the anticoagulant effect of warfarin, and to promote the rational use of warfarin.
METHODS: We collected the medical records of 125 hospitalized patients who used warfarin from January 2018 to December 2019. Statistical analysis was performed on characteristics such as gender, age, treatment, diabetes, hyperlipidemia, hyperthyroidism, hypothyroidism, hepatitis, renal insufficiency, and nephritis; along with other pathological factors, such as aspirin, clopidogrel, spironolactone, amiodarone, amlodipine, trimetazidine, bisoprolol, isosorbide, atorvastatin, furosemide, digoxin, metoprolol, acarbose, levamlodipine, enoxaparin, moxifloxacin, levofloxacin, other drug interactions, and comorbidities.
RESULTS: Gender and age did not have a significant effect on the efficacy of warfarin. Infection and bleeding extended the number of days of warfarin administration. Acarbose, enoxaparin, and moxifloxacin had a likely effect on warfarin treatment-related indicators.
CONCLUSIONS: Warfarin anticoagulation is affected by many factors. Therefore, medical personnel should pay close attention to the impact of these factors on the anticoagulant effect of warfarin. This study found that warfarin-related bleeding adverse drug reactions and anticoagulant effects have a significant association. Bleeding not only affected the total number of days hospitalized, but also extended the number of days of warfarin administration. However, in terms of patients\' pathological states, international normalized ratio values combined with drugs used were not associated with disease and may only be a reference for bleeding risk.
METHODS: We collected the medical records of 125 hospitalized patients who used warfarin from January 2018 to December 2019. Statistical analysis was performed on characteristics such as gender, age, treatment, diabetes, hyperlipidemia, hyperthyroidism, hypothyroidism, hepatitis, renal insufficiency, and nephritis; along with other pathological factors, such as aspirin, clopidogrel, spironolactone, amiodarone, amlodipine, trimetazidine, bisoprolol, isosorbide, atorvastatin, furosemide, digoxin, metoprolol, acarbose, levamlodipine, enoxaparin, moxifloxacin, levofloxacin, other drug interactions, and comorbidities.
RESULTS: Gender and age did not have a significant effect on the efficacy of warfarin. Infection and bleeding extended the number of days of warfarin administration. Acarbose, enoxaparin, and moxifloxacin had a likely effect on warfarin treatment-related indicators.
CONCLUSIONS: Warfarin anticoagulation is affected by many factors. Therefore, medical personnel should pay close attention to the impact of these factors on the anticoagulant effect of warfarin. This study found that warfarin-related bleeding adverse drug reactions and anticoagulant effects have a significant association. Bleeding not only affected the total number of days hospitalized, but also extended the number of days of warfarin administration. However, in terms of patients\' pathological states, international normalized ratio values combined with drugs used were not associated with disease and may only be a reference for bleeding risk.
摘要：
背景：为了研究影响华法林抗凝作用的各种因素，促进华法林的合理使用。
方法：我们收集了2018年1月至2019年12月使用华法林的125例住院患者的病历。对性别、年龄,治疗,糖尿病,高脂血症,甲状腺功能亢进,甲状腺功能减退,肝炎，肾功能不全,和肾炎；以及其他病理因素，比如阿司匹林,氯吡格雷,螺内酯,胺碘酮,氨氯地平,曲美他嗪,比索洛尔,异山梨醇,阿托伐他汀,呋塞米,地高辛,美托洛尔,阿卡波糖,左旋氨氯地平,依诺肝素,莫西沙星,左氧氟沙星,其他药物相互作用，和合并症。
结果：性别和年龄对华法林的疗效没有显著影响。感染和出血延长了华法林给药的天数。阿卡波糖,依诺肝素,和莫西沙星可能对华法林治疗相关指标有影响.
结论：华法林抗凝受到多种因素的影响。因此,医务人员应密切关注这些因素对华法林抗凝效果的影响。本研究发现华法林相关出血不良反应与抗凝作用有显著关联。出血不仅影响住院天数,而且延长了华法林给药的天数。然而,就患者的病理状态而言，国际标准化比率值与所用药物没有相关性,可能仅作为出血风险的参考.
方法：我们收集了2018年1月至2019年12月使用华法林的125例住院患者的病历。对性别、年龄,治疗,糖尿病,高脂血症,甲状腺功能亢进,甲状腺功能减退,肝炎，肾功能不全,和肾炎；以及其他病理因素，比如阿司匹林,氯吡格雷,螺内酯,胺碘酮,氨氯地平,曲美他嗪,比索洛尔,异山梨醇,阿托伐他汀,呋塞米,地高辛,美托洛尔,阿卡波糖,左旋氨氯地平,依诺肝素,莫西沙星,左氧氟沙星,其他药物相互作用，和合并症。
结果：性别和年龄对华法林的疗效没有显著影响。感染和出血延长了华法林给药的天数。阿卡波糖,依诺肝素,和莫西沙星可能对华法林治疗相关指标有影响.
结论：华法林抗凝受到多种因素的影响。因此,医务人员应密切关注这些因素对华法林抗凝效果的影响。本研究发现华法林相关出血不良反应与抗凝作用有显著关联。出血不仅影响住院天数,而且延长了华法林给药的天数。然而,就患者的病理状态而言，国际标准化比率值与所用药物没有相关性,可能仅作为出血风险的参考.
